BCBS Says Generic Xyrem Delay Was Antitrust Scheme

Law360 (July 14, 2020, 8:51 PM EDT) -- Blue Cross Blue Shield Association has accused Jazz Pharmaceuticals in California federal court of paying off generic-drug makers to delay their rival versions of the pharmaceutical giant's brand name narcolepsy drug Xyrem, arguing the alleged scheme caused buyers to overpay for the drug.

In a proposed class action complaint filed Monday in the U.S. District Court for the Northern District of California, BCBS said that Jazz schemed with generics makers like Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Ltd. and Endo International PLC subsidiary Par Pharmaceuticals Inc. to delay competition with Xyrem, which has annual sales of more than $1.4 billion,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!